Skip to main content
. 2022 Feb 16;23(4):2193. doi: 10.3390/ijms23042193

Figure 3.

Figure 3

Analysis of BCL-xL expression in hematological malignancies. Bioinformatic analysis of BCL-xL expression was revised in ONCOMINE data base using different datasets (* p < 0.05). (A) The analysis of Basso et al. [29] of BCL-xL expression in different hematological malignancies including subtypes of lymphoma, leukemia, and multiple myeloma. (B) In Storz et al. [30], we observe higher expression levels of BCL-xL expression in DLBCL and MZBCL vs. tonsil used as a control (** p < 0.01).